|
1. |
Cardiovascular and Pulmonary Complications of Obesity:An Overview |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 213-214
Martin Alpert,
Preview
|
PDF (47KB)
|
|
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
2. |
Obesity and Coronary Heart Disease |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 215-224
James Alexander,
Preview
|
PDF (128KB)
|
|
摘要:
Obesity is commonly cited as a risk factor for the development of coronary heart disease (CHD). Epidemiologic studies tend to support this contention, particularly those focusing on patients with central obesity. Such studies however, are imprecise and prone to misclassification bias. Angiographic and post mortem studies have demonstrated little or no correlation of total fat mass and coronary atherosclerosis except in those with abdominal obesity. There is a strong association of obesity, particularly central obesity, and traditional risk factors for CHD such as hypertension, type II diabetes mellitus, and dyslipidemia. There may also be an association between obesity and several nontraditional risk factors such as hyperhomocystinemia, elevated Lp(a) levels and factors that increase thrombogenesis. Obesity may also alter endothelial function. Weight loss, although associated with favorable modification of multiple risk factors for CHD, has not been shown to independently and definitively reduce CHD risk.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
3. |
Obesity Cardiomyopathy:Pathophysiology and Evolution of the Clinical Syndrome |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 225-236
Martin Alpert,
Preview
|
PDF (186KB)
|
|
摘要:
Obesity produces an increase in total blood volume and cardiac output because of the high metabolic activity of excessive fat. In moderate to severe cases of obesity, this may lead to left ventricular dilation, increased left ventricular wall stress, compensatory (eccentric) left ventricular hypertrophy, and left ventricular diastolic dysfunction. Left ventricular systolic dysfunction may occur if wall stress remains high because of inadequate hypertrophy. Right ventricular structure and function may be similarly affected by the aforementioned morphologic and hemodynamic alterations and by pulmonary hypertension related to the sleep apnea/obesity hypoventilation syndrome. The term obesity cardiomyopathy is applied when these cardiac structural and hemodynamic changes result in congestive heart failure. Obesity cardiomyopathy typically occurs in persons with severe and long-standing obesity. The predominant causes of death in those with obesity cardiomyopathy are progressive congestive heart failure and sudden cardiac death.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
4. |
Management of Obesity Cardiomyopathy |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 237-241
Martin Alpert,
Preview
|
PDF (115KB)
|
|
摘要:
Therapy of acute exacerbations of congestive heart failure associated with obesity cardiomyopathy consists of dietary salt restriction, inspired oxygen, diuretics, and angiotensin-converting enzyme inhibitors or, if left ventricular systolic dysfunction is present, hydralazine/isosorbide dinitrate. Digitalis may be indicated in selected cases. These measures may also be useful chronically in association with weight loss. Substantial weight loss is capable of reversing all of the hemodynamic abnormalities associated with obesity except elevation of left ventricular filling pressure. Substantial weight loss may also reduce left ventricular mass and improve left ventricular diastolic filling in those with left ventricular hypertrophy before weight loss. Left ventricular systolic function also improves after weight loss in those with impaired pre-weight-loss systolic function. These beneficial effects of weight loss occur partly because of favorable alterations in left ventricular loading conditions. Substantial weight loss in patients with congestive heart failure associated with obesity cardiomyopathy produces a reversal of many of the clinical manifestations of cardiac decompensation and improves New York Heart Association functional class in most patients.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
5. |
Obesity, Hypertension, and the Heart |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 242-248
Vashu Thakur,
Robert Richards,
Efrain Reisin,
Preview
|
PDF (269KB)
|
|
摘要:
Hypertension occurs more commonly in obese than in lean persons at virtually every age. A variety of endocrine, genetic, and metabolic mechanisms have been linked to the development of obesity hypertension. These include insulin resistance and hyperinsulinemia, increased serum aldosterone levels, salt sensitivity and expanded plasma volume in the presence of increased peripheral vascular resistance, a genetic predisposition, and possibly increased leptin levels. Pressure and volume overload are present in obese hypertensives. This leads to a mixed eccentric-concentric form of left ventricular hypertrophy and increases the predisposition to congestive heart failure. Weight loss, even in modest decrements, is effective in reducing obesity-hypertension, possibly by ameliorating several of the proposed pathophysiologic mechanisms. There are currently no specific recommendations concerning pharmacotherapy of obesity-hypertension because each drug group has pros and cons.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
6. |
Pulmonary Complications of Obesity |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 249-279
Steven Koenig,
Preview
|
PDF (475KB)
|
|
摘要:
Obesity can profoundly alter pulmonary function and diminish exercise capacity by its adverse effects on respiratory mechanics, resistance within the respiratory system, respiratory muscle function, lung volumes, work and energy cost of breathing, control of breathing, and gas exchange. Weight loss can reverse many of the alterations of pulmonary function produced by obesity. Obesity places the patient at risk of aspiration pneumonia, pulmonary thromboembolism, and respiratory failure. It is the most common precipitating factor for obstructive sleep apnea and is a requirement for the obesity hypoventilation syndrome, both of which are associated with substantial morbidity and increased mortality. There are numerous medical and surgical therapies for obstructive sleep apnea and obesity hypoventilation. Weight reduction in the obese is among the most effective of these measures.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
7. |
Cardiovascular Complications of Weight Reduction Diets |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 280-284
Waqas Ahmed,
Margaret Flynn,
Martin Alpert,
Preview
|
PDF (97KB)
|
|
摘要:
Weight reduction diets may reduce the severity of risk factors for coronary heart disease such as diabetes mellitus, hypertension, and dyslipidemia. Several case reports and small studies of patients receiving starvation diets have reported hypotension and sudden cardiac death. Myofibrillar damage was documented in 1 case. Very-low-calorie diets are generally safe and well-tolerated. However, low QRS voltage, QT interval prolongation, and both nonsustained ventricular arrhythmias and sudden cardiac death have been described in subjects treated with such diets. Orthostatic hypotension may complicate very-low-calorie protein diets because of sodium depletion and depressed sympathetic nervous system activity. Bariatric surgery is associated with disproportionately high mortality rates in both the perioperative and postoperative periods.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
8. |
Appetite Suppressants and Valvular Heart Disease |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 285-291
Neil Weissman,
Preview
|
PDF (413KB)
|
|
摘要:
The association between valvular heart disease and diet pills was discovered several years ago in a small cohort of patients. Subsequent uncontrolled surveys and reports suggested a prevalence of cardiac abnormalities as high as 30%. These results led to widespread concern by millions of appetite suppressant users and the withdrawal of both fenfluramine and dexfenfluramine from the market. Through this review of the literature, it becomes apparent that we have better defined the association between valvular heart disease and appetite suppressants; nonetheless, many questions and controversies remain. Most large scale, multicenter, controlled studies have shown that a prevalence of significant valve regurgitation is between 2 and 12% and that the likelihood of disease increases with increasing dose and/or duration of appetite suppressant use, but several other issues, such as the mechanism of action, remain unanswered.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
9. |
Anorectic Drugs and Pulmonary Hypertension from the Bedside to the Bench |
|
The American Journal of the Medical Sciences,
Volume 321,
Issue 4,
2001,
Page 292-299
Evangelos Michelakis,
E. Kenneth Weir,
Preview
|
PDF (500KB)
|
|
摘要:
Anorectic drugs have been used for more than 30 years as an aid in weight reduction for obese persons. The use of aminorex, an amphetamine analog that increases norepinephrine levels in the central nervous system, led to an epidemic of primary pulmonary hypertension (PPH) in Europe in the late 1960s and early 1970s. The use of fenfluramine and later dexfenfluramine [drugs that inhibit 5-hydroxytryptamine (5-HT) release and reuptake and increases 5-HT and thus 5-HT secretion in the brain] was associated with a second epidemic of PPH. All of these drugs have been voluntarily withdrawn from the market. The pathogenesis of PPH in patients treated with these agents is uncertain, but recent evidence suggests that potassium channel abnormalities and vasoactive and proliferative properties of 5-HT may play a role. There is increasing experimental evidence suggesting that aminorex, fenfluramine and dexfenfluramine inhibit 4-aminopyridine-sensitive currents in potassium channels resulting in vasoconstriction in pulmonary resistance vessels and perhaps smooth muscle cell proliferation. 5-HT causes pulmonary artery vasoconstriction and smooth muscle cell proliferation. Its levels are known to be high in those with fenfluramine-induced PPH. However, a firm cause-and-effect relationship has not yet been established. One potentially beneficial effect of the epidemics of anorectic-related PPH is that it may have provided important insights into the causes of PPH unrelated to anorectic agents.
ISSN:0002-9629
出版商:OVID
年代:2001
数据来源: OVID
|
|